New Release: Alpha testing version has been released.

Benzoyl Peroxide

D10A - Anti-acne preparations for topical use ATC D10AE01 Small molecule approved 1984 Topical Natural product

JFDA label: Benoxyphil Gel

Mechanism of Action

— Releases active oxygen

Indications

Approved

  • Acne vulgaris, acne rosacea

Contraindications

Source: Lexicomp

  • Hypersensitivity to benzoyl peroxide or any other component of the formulation Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Other (6)

Common Dermatologic: Contact dermatitis · desquamation · erythema · skin irritation · stinging of the skin · xeroderma

Dosing

Source: Lexicomp

Acne: Topical formulations: Apply sparingly once daily; gradually increase to 2 to 3 times/day if needed. If excessive dryness or peeling occurs, reduce dose frequency or concentration. If excessive stinging or burning occurs, remove with mild soap and water; resume use the next day. Topical cleansers: Wash once or twice daily; control amount of drying or peeling by modifying dose frequency or concentration.
(For additional information see "Benzoyl peroxide: Pediatric drug information") Children ≥12 years and Adolescents: Refer to adult dosing.
Refer to adult dosing.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.

Warnings & Precautions

Source: Lexicomp

Bleaching effects

May bleach hair, colored fabric, or carpet.

Hypersensitivity reaction

Rare but serious and potentially life-threatening allergic reactions or severe irritation have been reported with use of topical OTC benzoyl peroxide or salicylic acid containing products; it has not been determined if the reactions are due to the active ingredients (benzoyl peroxide or salicylic acid), the inactive ingredients, or a combination of both. Hypersensitivity reactions may occur within minutes to a day or longer after product use and differ from local skin irritation (redness, burning, dryness, itching, peeling or slight swelling) that may occur at the site of product application. Treatment should be discontinued if hives or itching develop; patients should seek emergency medical attention if reactions such as throat tightness, difficulty breathing, feeling faint, or swelling of the eyes, face, lips, or tongue develop. Before using a topical OTC acne product for the first time, consumers should apply a small amount to 1 or 2 small affected areas for 3 days to make sure hypersensitivity symptoms do not develop. (FDA Drug Safety Communication 2014).

Skin irritation

Skin irritation (eg, burning, itching, peeling, redness, swelling) may occur; discontinue use if severe irritation develops. Dosage form specific issues:

Benzyl alcohol and derivatives

Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling. Concurrent drug therapy issues:

Sulfone products

Concomitant use of benzoyl peroxide with sulfone products (eg, dapsone, sulfacetamide) may cause temporary discoloration (yellow/orange) of facial hair and skin. Application of products at separate times during the day or washing off benzoyl peroxide prior to application of other products may avoid skin discoloration (Dubina 2009). Other warnings/precautions:

Appropriate use

For external use only; avoid contact with eye, eyelids, lips, mouth, and mucous membranes. Inform patients to use skin protection (eg, sunscreen) and minimize prolonged exposure to sun or tanning beds.

Pregnancy & Lactation

Pregnancy

FDA category C

Animal reproduction studies have not been conducted; ~2% of the applied dose is expected to be absorbed systemically (Akhavan, 2003).

Lactation

It is not known if benzoyl peroxide is excreted in breast milk. The manufacturer recommends that caution be exercised when administering benzoyl peroxide to nursing women.

Chemistry & Properties

2D structure
FormulaC14H10O4
Molecular weight242.23 g/mol
IUPAC namebenzoyl benzenecarboperoxoate
CAS94-36-0
PubChem CID7187
InChIKeyOMPJBNCRMGITSC-UHFFFAOYSA-N
logP2.62 (XLogP 3.5)
Polar surface area52.6 Ų
H-bond acceptors / donors4 / 0
Drug-likeness (QED)0.60
Lipinski violations0
SMILESO=C(OOC(=O)c1ccccc1)c1ccccc1

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrantNo

Enzyme interactions

EnzymeRoleDetail
CYP1A2Inhibitor
CYP2C8Inhibitor

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Registered Products (6)

BrandForm / strengthPackAgentCitizen (JOD)
Benoxyphil Gel Gel 5 % 40 g tube PHILADELPHIA PHAEMACEUTICALS.COMP/JORDAN 1.700
Benoxyphil Gel Gel 10 % 40 g tube PHILADELPHIA PHAEMACEUTICALS.COMP/JORDAN 1.970
Panoxyl Cream Cream 5 % 40 g tube Suleiman Tannous & Sons Co. Ltd 2.170
Benzac AC Gel 5 % 60 g tube IBN CINA DRUG STORE 3.260
Adacline Gel Gel 0.75 g, 0.03 g 30 GM/1 UNT PELLA PHARMACEUTICALS CO.LTD/JORDAN 6.550
Epiduo Gel Gel 2.5 %, 0.1 % 30 GM IBN CINA DRUG STORE 12.780